Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.
Also called NCT02946632
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 104 participants
- Registry
-
NCT02946632
-
- Other papers using this trial's data
- Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02946632. Randomized; no masking; primary purpose treatment. Start 2016-12 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type II
- Intervention (Drug)
- triple combination therapy
- Intervention (Drug)
- Stepwise add-on therapy
- Lead sponsor
- Korea University Anam Hospital
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02946632- Content hash
c5eb566dbc3ae3e2ce6202ce2704e2fe908ea958abc817ffffaa30a57d01ed5e